WHO Prequalification of In Vitro Diagnostics
PUBLIC ASSESSMENT REPORT

Product: cobas MTB
WHO reference number: PQDx 10306-118-00

cobas MTB with product code 09040579190, manufactured by Roche Diagnostics GmbH, CE-marked regulatory version, was accepted for the WHO list of prequalified in vitro diagnostics and was listed on 20 April 2026.

Summary of the WHO Prequalification Assessment for the cobas MTB

	Date	Outcome
Prequalification listing	20 April 2026	listed
Dossier assessment	15 May 2025	MR
Product performance evaluation	16 April 2026	MR

MR: Meets Requirements

Intended use

According to the intended use claim from Roche Diagnostics GmbH (IFU version 09348468001-03EN), "*cobas MTB for use on the cobas 5800/6800/8800 systems is an automated, qualitative in vitro diagnostic test, that utilizes real-time polymerase chain reaction (PCR), for the direct detection of Mycobacterium tuberculosis complex (MTBC) DNA, in human respiratory specimens; including raw sputum, and digested and decontaminated (N-acetyl-L-cysteine/NaOH [NALC-NaOH]-treated) sputum and bronchoalveolar lavage (BAL) samples.*

This test is for use with specimens from patients who are suspected of Mycobacterium tuberculosis infection, and who are not taking antituberculosis therapy. This test is intended as an aid in the diagnosis of pulmonary tuberculosis, and in conjunction with other laboratory findings, as well as clinical signs and symptoms."

Test kit contents

Component	Description	Quantity per kit
cobas MTB, product code 09040579190 (384 test cassette)	Proteinase Solution (PASE)	38 mL
	DNA Internal Control (DNA-IC)	38 mL
	Elution Buffer (EB)	38 mL

	Master Mix Reagent 1 (MMX-R1)	14.5 mL
	MTB Master Mix Reagent 2 (MTB MMX-R2)	17.5 mL

Materials required but not provided

Item	Description	Quantity per kit
cobas MTB Positive Control Kit	For use on the cobas 5800 system, and the cobas 6800/8800 systems with software version 2.0 or higher (P/N 09040587190). For use on the cobas 6800/8800 systems with software version 1.4 (P/N 07544812190 or P/N 09040587190.	16 mL (16 x 1 mL)
cobas Buffer Negative Control Kit	For use on the cobas 5800 system, and the cobas 6800/8800 systems with software version 2.0 or higher (P/N 09051953190) For use on the cobas 6800/8800 systems with software version 1.4 (P/N 07002238190 or P/N 09051953190)	16 mL (16 x 1 mL)
cobas omni reagents for sample preparation	cobas omni MGP Reagent (MGP) Store at 2-8°C (P/N 06997546190)	480 tests
	cobas omni Specimen Diluent (SPEC DIL) Store at 2-8°C (P/N 06997511190)	4 x 875 mL
	cobas omni Lysis Reagent (LYS) Store at 2-8°C (P/N 06997538190)	4 x 875 mL
	cobas omni Wash Reagent (WASH) Store at 15-30°C (P/N 06997503190)	4.2 L

Instrumentation and software required

The cobas 5800 software, the cobas 6800/8800 systems software and cobas MTB analysis package for the cobas 5800/6800/8800 systems must be installed.

For the cobas 5800 and the cobas 6800/8800 systems software version 2.0 or higher, the x800 Data Manager software and PC (or server) will be provided with the system.

For the cobas 6800/8800 systems with software version 1.4, the Instrument Gateway (IG) server will be provided with the system.

Equipment	Product Number (P/N)
cobas 5800 System	08707464001
cobas 6800 System	05524245001 and 09575154001
cobas 8800 System	05412722001 and 09575154001
Sample Supply Module for cobas 6800/8800 systems	06301037001 and 09936882001

Storage Temperature and Stability

Parameter	Condition
Storage Temperature	2-8 °C
Shelf Life (from manufacture)[1]	24 months.

Dossier review

The manufacturer submitted a product dossier as per the "Instructions for compilation of a product dossier" (PQDx_018). The information (data and documentation) submitted in the product dossier was reviewed by WHO staff and external technical experts (assessors) appointed by WHO.

The manufacturer's responses to the discrepancies found during dossier screening and assessment findings were accepted on 15 May 2025.

Based on the product dossier screening and assessment findings, the product dossier for the cobas MTB meets WHO prequalification requirements.

[1] The assigned device shelf-life is based on stability data generated from the date of manufacture. The finished goods shelf-life, calculated from the date of packaging completion, may be shorter depending on the time elapsed between manufacture and final packaging of the device.

Manufacturing site inspection

The inspection of the manufacturing site(s) was conducted to assess whether the manufacturer's quality management system (QMS) and manufacturing practices are in alignment with:
(i) applicable international standards, such as ISO 13485 (Medical devices – Quality management systems – Requirements for regulatory purposes);
(ii) the manufacturer's own documented procedures and quality requirements; and
(iii) other relevant international standards and guidelines applicable to in vitro diagnostic (IVD) medical devices. The WHO's Public Inspection Reports are accessible at:

https://extranet.who.int/pqweb/vitro-diagnostics/who-public-inspection-reports

Product performance evaluation

cobas MTB was evaluated by the ICMR- National Institute for Research in Tuberculosis, Thiruvallur, India on behalf of in the third and fourth quarter of 2025 and first quarter of 2026, according to protocol IVD/PR/4/P23, version 2.0.

The evaluation was performed with cobas MTB (product code 09040579190) in combination with the cobas 5800 System.

Clinical performance evaluation

In this limited laboratory-based evaluation of clinical performance characteristics, a panel of 302 sputum specimens was used. Specimens were characterized by fluorescence smear microscopy, liquid culture (MGIT) and speciation, and by Xpert MTB/RIF Ultra, which was used as comparator method.

Clinical performance characteristics in comparison with agreed reference standard			
	Overall	**Smear-positive**	**Smear-negative**
Sensitivity % (95% CI) (N=102)	98.0% (93.1%-99.8%)	100% (96.4%-100%)	93.3% (77.9%-99.2%)
Specificity % (95% CI) (N= 200)	99.5% (97.2%-100%)		
Invalid rate % (N= 302)	0%		
Difference in sensitivity with comparator method	-1% (Tango 95% CI: -6.0% to 3.6%)		

Difference in specificity with comparator method	-0.5% (Tango 95% CI: -2.8% to 1.4%)

Analytical performance evaluation

Analytical performance characteristics	
Limit of detection (LoD) using the WHO International Standard for M. tuberculosis (H37Rv) DNA for NAT-based assays (NIBSC code: 20/152)	The LoD for *M. tuberculosis* detection was estimated at 311.6 IU/mL (95% CI: 65.6-557.5) for *M. tuberculosis* detection.
Reproducibility	The hit rate for detection of *M. tuberculosis* (sensitive) at approx. 1000 CFU/mL was 100% (39/39) and hit rate for negative results was 100% (40/40) with negative specimen.
Inclusivity, exclusivity	The following mycobacteria (MTBC) were detected: *M. bovis*, *M. africanum.* The following mycobacteria (NTM) were not detected: *M. avium*, *M. kansasii*, *M. intracellulare*, in agreement with manufacturer's claim.
Cross-contamination	No cross-contamination was observed when high positive and negative specimens were tested together.

Operational characteristics and ease of use

This assay requires laboratory equipment and cannot be performed in laboratories with limited facilities or in non-laboratory settings. The instrument requires a stable source of electricity and significant physical space. Furthermore, training and implementation of good laboratory practice is essential to obtaining accurate results. Adequate technical support from manufacturer or representative is critical. Several breakdowns occurred during the evaluation, which required site visits by manufacturer's engineer.

The assay was found easy to use by the operators performing the evaluation.

Key operational characteristics	
Time to result for one run	270 minutes (4.5 hours) and every 60 minutes thereafter.
Operator hands-on time for one run	60 minutes (10 minutes - Precision pipetting, 25 minutes - sonication, centrifugation - 5 minutes, Barcoding - 10 minutes, Sample loading (uncapping secondary tubes), giving orders to the samples 5 to 10 minutes)
Level of automation	Manual specimen processing (including one-hour inactivation and sonication). Automatic DNA extraction and PCR amplification.

Quality controls	Kits quality controls (MTBC Positive Control and cobas Buffer Negative Control) are provided by the manufacturer and should be purchased separately.
Operating temperature	15°C - 35 °C
Result display and connectivity	Results are displayed on the instrument and connected computer. They may be printed using a standard printer. The results can be exported to the laboratory information system and other health information systems.
Power sources	Main power The use of a UPS is recommended, as stable electricity is required
Biosafety *(outside of infectious specimen handling)*	Operators reported biosafety considerations. The following warnings regarding the use of Microbial Inactivation Solution (MIS), Lysis reagent are mentioned in the IFU: *If spillage of samples in MIS (which contains guanidine thiocyanate) occurs, do not allow it to come in contact with sodium hypochlorite containing disinfectants such as bleach. This mixture can produce a highly toxic gas. *cobas omni Lysis Reagent and MIS contain guanidine thiocyanate, a potentially hazardous chemical. Avoid contact of reagents with the skin, eyes, or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, burns can occur. *Do not allow cobas omni Lysis Reagent or MIS, which contain guanidine thiocyanate, to contact sodium hypochlorite (bleach) solution. This mixture can produce a highly toxic gas.
Waste	The volume of liquid waste is approx. 5 to 6 liters per 10-15 runs. The volume of solid waste is approx. 1 large size biohazard bag per 10-15 runs. Waste disposal requires specific measures in addition to usual laboratory biohazard waste disposal procedures: liquid waste should be discarded only in the labs which have specialized effluent decontamination systems (EDS) for liquid waste, since MIS contains guanidine thiocyanate.
Calibration	No calibration needed.

Maintenance	Weekly maintenance is required and manually done by user and monthly maintenance automatically done by the instrument.
Other specific requirements	Space requirements sufficient to accommodate the cobas system (Dimensions of cobas 5800 system: 135 x 185 x 81 cm (W x H x D); Weight: 623 kg) A connected computer.

Based on these results, the performance evaluation for cobas MTB meets the WHO prequalification requirements.

Labelling review

The labelling submitted for the cobas MTB was reviewed by WHO staff and external technical experts appointed by WHO. The review evaluated the labelling for clarity and consistency with the information submitted in the product dossier, alignment with international guidance and standards, and suitability for the intended users and settings in WHO Member States, including low- and middle-income countries.

The table below provides traceability of the labelling documents reviewed during the assessment, including document titles, version numbers, approval dates, and control identifiers.

Controlled Labelling References

Table 1 for cobas MTB (384T) – Assay Labels

Document Type	Document Title	Version / Revision	Date Approved	Controlled Document No.
IFU	cobas MTB Nucleic acid test for use on the cobas 5800/6800/8800 Systems - CE-IVD - English	03	12-Dec-2024	ART9348468001EN
Label – UDI	LBL UDI COBAS 58/68/8800 MTB 384T	02	11-Nov-2022	ART9040579190
Label – Carton	CARTON COBAS 58/68/88 MTB 384T IVD	03	06-Jan-2026	ART9348204001
Label – Cassette	LBL CSTE COBAS 58/68/88 MTB 384T IVD	01	31-May-2022	ART9348336001
Label – PIC	INSERT PROD INFO C58/68/88 MTB 384T IVD	05	13-Apr-2026	ART9348433001

Labels



cobas® MTB

REF 09040579190

IVD

2°C 8°C

Rx Only

cobas®

CONTENT

MTB Cassette	x 1
MMX-R1	14.5 mL
MTB MMX-R2	17.5 mL
EB	38 mL
DNA IC	38 mL
PASE	38 mL

09348204001-03

MTB

Manufactured in the United States

Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim, Germany

Made in USA

MTB

cobas® MTB

cobas®

0123

MTB

UDI label here

Drawing: CAM12010

REF (240) 09040579190

GTIN (01)00875197006605

UDI

01

LOT (10) Z12345

2038-01-31

2030-01-31


cobas® MTB
09040579190
Σ 384
8°C
2°C
09348336001-01
IVD
Manufactured in the United States
Roche Diagnostics GmbH
68305 Mannheim, Germany
LOT
32 mm x 12.7 mm
unvarnished
area

cobas® MTB

IVD

KIT LOT

cobas® 5800
Non-USA



cobas® 5800 MTB ASAP 1.1.0 or higher
or
cobas® x800 MTB ASAP 1.1.0 or higher
cobas® 5800 Software Version 1.0.2 or higher

cobas® 6800/8800 for instrument software version 1.4
Non-USA



cobas® MTB ASAP 12.1.0 or higher
cobas® 6800/8800 System Software Version 1.4 or higher

cobas® 6800/8800 for instrument software version 2.0
Non-USA



cobas® x800 MTB ASAP 1.1.0 or higher
cobas® 6800/8800 System Software Version 2.0 or higher

Non-USA

website: http://e-labdoc.roche.com
Method Sheet Catalog No.: 09040579190 Doc Rev. 4.0 or higher

Please contact your local Roche representative if you require a printed copy free of charge or need technical support to access the package insert./ Bei Ihrer zuständigen Roche-Vertretung erhalten Sie einen kostenfreien Ausdruck oder technische Unterstützung für den Zugriff auf die Packungsbeilage./ Veuillez contacter votre représentant Roche local pour obtenir un exemplaire papier gratuit ou une assistance technique pour accéder à la notice./ Contattare il rappresentante Roche locale per ottenere gratuitamente una copia stampata o richiedere istruzioni per reperire il foglio illustrativo./ Póngase en contacto con su representante local de Roche si necesita una copia impresa gratuita o ayuda del servicio técnico para acceder al boletín técnico./ Se desejar uma cópia impressa gratuita ou necessitar de assistência técnica para aceder ao folheto informativo, entre em contacto com o representante local da Roche./ Kontakt den lokale Roche-repræsentant, hvis du ønsker en gratis skriftlig kopi eller har brug for teknisk support for at få adgang til indlægssedlen./ Kontakta din Roche-representant om du vill ha en pappersversion kostnadsfritt eller om du behöver teknisk support för att komma åt bipacksedeln./ Aby otrzymać darmową drukowaną wersję lub jeśli zaistniały problemy techniczne z dostępem do ulotki dołączonej do opakowania, należy skontaktować się z miejscowym przedstawicielem firmy Roche./ Ak potrebujete bezplatnú vytlačenú kópiu alebo ak potrebujete technickú pomoc ohľadne prístupu k príbalovým letákom, obráťte sa na miestneho zástupcu spoločnosti Roche.

Manufactured in the United States

Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim, Germany

09348433001-05

Instructions for Use[2]

[2] English version of the IFU was the one that was assessed by WHO. It is the responsibility of the manufacturer to ensure correct translation into other languages.

cobas® MTB

Nucleic acid test
for use on the cobas® 5800/6800/8800 systems

For in vitro diagnostic use

cobas® MTB	P/N: 09040579190
For use on the cobas® 5800 system	
cobas® MTB Positive Control Kit	P/N: 09040587190
cobas® Buffer Negative Control Kit	P/N: 09051953190
For use on the cobas® 6800/8800 systems	
cobas® MTB Positive Control Kit	P/N: 07544812190 or P/N: 09040587190
cobas® Buffer Negative Control Kit	P/N: 07002238190 or P/N: 09051953190

Table of contents

Intended use

cobas® MTB for use on the **cobas**® 5800/6800/8800 systems is an automated, qualitative in vitro diagnostic test, that utilizes real-time polymerase chain reaction (PCR), for the direct detection of *Mycobacterium tuberculosis* complex (MTBC) DNA, in human respiratory specimens; including raw sputum, and digested and decontaminated (N-acetyl-L-cysteine/NaOH [NALC-NaOH]-treated) sputum and bronchoalveolar lavage (BAL) samples.

This test is for use with specimens from patients who are suspected of *Mycobacterium tuberculosis* infection, and who are not taking antituberculosis therapy. This test is intended as an aid in the diagnosis of pulmonary tuberculosis, and in conjunction with other laboratory findings, as well as clinical signs and symptoms.

Summary and explanation of the test

Background

Tuberculosis is a bacterial infection caused by the MTBC that is both a major global health problem and a leading cause of infectious disease deaths worldwide.[1] The World Health Organization (WHO) estimates that about one-quarter of the world's population are infected with MTB, with an estimated 10.6 million new TB infections and 1.3 million deaths in 2022.[1] People living with HIV/AIDS (PLWA) were estimated to have 167,000 of the 1.3 million deaths.[1]

The *M. tuberculosis* complex comprises a group of closely related species within the genus of *Mycobacterium* that cause disease in humans and animals and includes *M. tuberculosis*, *M. bovis*, *M. bovis* BCG (Bacillus Calmette-Guérin), *M. africanum*, *M. canetti*, *M. microti*, *M. caprae*, *M. pinnipedii*, *M. mungi*, *M. suricattae, M. orygis,* dassie bacillus and chimpanzee bacillus. While infection with any member of the MTB complex can lead to tuberculosis, *M. tuberculosis* is the most common cause. Pulmonary disease is the most common illness caused by MTB complex. Extra-pulmonary disease can occur, but is relatively more prevalent in children. *M. bovis* is the cause of tuberculosis in up to 2.8% of patients in different geographical settings.[2] Members of MTB complex other than *M. bovis* and *M. tuberculosis* are less common causes of disease in humans. *M. tuberculosis* has been associated with elephants, both in captive and wild.[3] *M. africanum* has been associated with tuberculosis in West African countries, *M. canetti* in the Horn of Africa and *M. orygis* causes tuberculosis in humans and animals from Africa to South Asia. *M. caprae* is considered a subspecies of *M. bovis*. *M. microti* causes disease primarily in rodents, *M. pinnipedii* is associated with disease in seals and *M. suricattae* causes tuberculosis in meerkats of South Africa. *M. mungi* was identified as a cause of tuberculosis disease in banded mongoose.[4]

Tuberculosis is spread person to person via respiratory droplets. Most people who are infected with *M. tuberculosis* are asymptomatic and are able to contain the disease following primary infection. This is known as latent tuberculosis infection. Latent infections can last for decades and in most cases never result in clinical disease. In some people, the organism overcomes immune defenses, resulting in progression from latent tuberculosis infection to active tuberculosis. This usually occurs either within the first two years of infection, or after long periods of latency. Overall, there is a 5-10% risk for patients with latent infection to develop active TB disease; however, the risk varies due to many factors, and may be substantially increased by immunosuppression such as treatment with "biologicals"[5] (i.e., TNF-inhibitors) and HIV infection.[6,7] Persons with active pulmonary TB may produce droplets by coughing, speaking, or during medical procedures. Persons with active pulmonary disease are considered highly infectious and consequently diagnosis is imperative.

The diagnosis of active TB is based on clinical findings/suspicion, as well as laboratory and radiographic studies. Patients may be asked to provide respiratory specimens for acid-fast bacteria smear and mycobacterial culture, as well as direct nucleic acid amplification testing. It is imperative that mycobacterial culture be performed in addition to nucleic acid testing to

help mitigate the risk of false negative results, and to enable drug-susceptibility testing for those patients who are positive.

Treatment of tuberculosis involves prolonged administration of multiple drugs and is usually effective. However, treatment of MTB strains resistant to one or more drugs makes cure more difficult. Treatment of drug resistant and multi-drug resistant TB (MDR-TB) is complex and requires administration of multiple toxic drugs for a longer duration than for drug susceptible TB patients, with a lower likelihood of treatment success.[8] Treatment of more severe forms of polyresistant TB such as extensively resistant TB (XDR-TB) is associated with poorer outcomes than MDR-TB.[1]

The diagnosis of TB can be established based on clinical presentation, laboratory and radiographic findings, including acid-fast bacterial smears, mycobacterial cultures, and nucleic acid amplification tests. Additionally, assays that measure antibody or antigen response may also be used (e.g., tuberculin skin test, interferon-gamma [INFγ]-release assay (IGRAs)).[2] However, the tuberculin skin test and IGRA assays may be negative in active disease and cannot differentiate latent infection from active disease. The definitive diagnosis of the disease is confirmed by recovery of the causative organism in culture or by the direct detection of MTB complex nucleic acid in a clinical sample. Drug susceptibility testing (DST) is required to confirm appropriate empiric therapy but is time consuming, requiring several weeks for results depending on the method. Alternatively, drug resistance associated genetic markers can be detected directly from clinical specimens or from culture isolates using molecular methods for more rapid results. Given the infectious nature of MTB and the presence of emerging resistance, fast and accurate diagnosis is an important element of MTB treatment and control.[2]

Explanation of the test

cobas® MTB for use on the **cobas**® 5800/6800/8800 systems is an automated, qualitative real-time PCR test designed to detect MTB complex DNA in human respiratory specimens; including raw sputum specimens; and digested, and decontaminated NALC-NaOH-treated sputum and BAL sediments. The DNA Internal Control, used to monitor the entire sample preparation and PCR amplification process on the **cobas**® 5800/6800/8800 systems, is introduced into each specimen during sample processing. In addition, the test utilizes a low titer positive and a negative control.

Principles of the procedure

cobas® MTB is based on pre-analytic sample liquefaction and mycobacteria inactivation followed by sample sonication and fully automated sample preparation (nucleic acid extraction and purification) and PCR amplification and detection. Sample liquefaction and mycobacteria inactivation occur simultaneously during sample incubation with **cobas**® Microbial Inactivation Solution (MIS). Sonication of liquefied and inactivated sample is performed prior to loading onto the **cobas**® 5800/6800/8800 systems. The **cobas**® 5800 system is designed as one integrated instrument. The **cobas**® 6800/8800 systems consist of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the **cobas**® 5800 or **cobas**® 6800/8800 systems software which assigns test results for all tests as positive, negative or invalid. Results can be reviewed directly on the system screen, exported, or printed as a report.

Nucleic acid from patient samples, external controls and added internal control DNA (DNA-IC) molecules is simultaneously extracted. In summary, bacterial nucleic acid is released by chemical (**cobas**® Microbial Inactivation Solution [MIS], **cobas**® **omni** Lysis Reagent), enzymatic (proteinase), and physical (sonication) disruption of bacteria. The released nucleic acid binds to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured protein, cellular debris and potential PCR inhibitors are removed with subsequent wash steps and purified nucleic acid is eluted from the magnetic glass particles with elution buffer at elevated temperature.

Selective amplification of target nucleic acid from the sample is achieved by the use of target-specific forward and reverse primers for the MTB complex which are selected from highly-conserved regions within the respective target organism. MTB is detected by two selective sets of primers and two probes targeting separate regions (dual-target, 16S rRNA gene and *esx* genes - *esxJ, esxK*, *esxM*, *esxP*, and *esxW*). Selective amplification of DNA IC is achieved by the use of sequence-specific forward and reverse primers which are selected to have no homology with the MTB complex target regions. A thermostable DNA polymerase enzyme is used for PCR amplification. The target and DNA-IC sequences are amplified simultaneously utilizing a universal PCR amplification profile with predefined temperature steps and number of cycles. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythymidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon). Any contaminating amplicon from previous PCR runs are eliminated by the AmpErase enzyme, which is included in the PCR master mix, during the first thermal cycling step.[9] However, newly formed amplicons are not eliminated since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C.

The **cobas**® MTB master mix contains two detection probes specific for the MTB complex target sequences and one for the DNA-IC. The target specific probes are labeled with different fluorescent reporter dyes allowing simultaneous detection of MTB complex target and DNA-IC in two different target channels.[10,11] When not bound to the target sequence, the fluorescent signal of the intact probes is suppressed by a quencher dye. During the PCR amplification step, hybridization of the probes to the specific single-stranded DNA template results in cleavage of the probe by the 5' to 3' exonuclease activity of the DNA polymerase causing the separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye increases concomitantly. Real-time detection and discrimination of PCR products is accomplished by measuring the fluorescence of the released reporter dyes for the MTB complex targets and DNA-IC, respectively.

Reagents and materials

cobas® MTB reagents and controls

The materials provided for **cobas**® MTB can be found in Table 1. Materials required, but not provided can be found in Table 2, Table 3, Table 4, Table 10 to Table 12.

All unopened reagents and controls must be stored as recommended in Table 1 to Table 4.

Table 1 cobas® MTB

cobas® MTB

Store at 2-8°C
384 test cassette (P/N 09040579190)

Kit components	Reagent ingredients	Quantity per kit
Proteinase Solution (PASE)	Tris buffer, < 0.05% EDTA, calcium chloride, calcium acetate, 8% proteinase, glycerol EUH210: Safety data sheet available on request. EUH208: Contains Subtilisin from Bacillus subtilis. May produce an allergic reaction.	38 mL
DNA Internal Control (DNA-IC)	Tris buffer, < 0.05% EDTA, < 0.001% non-MTB related DNA construct, 0.002% Poly rA RNA (synthetic), < 0.1% Sodium azide	38 mL
Elution Buffer (EB)	Tris buffer, 0.2% Methyl-4 hydroxibenzoate	38 mL
Master Mix Reagent 1 (MMX-R1)	Manganese acetate, Potassium hydroxide, < 0.1% Sodium azide	14.5 mL
MTB Master Mix Reagent 2 (MTB MMX-R2)	Tricine buffer, potassium acetate, EDTA, glycerol, 18% dimethyl sulfoxide, < 0.12% dATP, dCTP, dGTP, dUTPs, < 0.1% Tween 20, < 0.1% sodium azide, < 0.1% Z05 DNA polymerase, < 0.1% AmpErase (uracil-N glycosylase) enzyme (microbial), < 0.01% Internal Control forward and reverse primers, < 0.01% Upstream and downstream MTB primers, < 0.01% Fluorescent-labeled oligonucleotide probes specific for MTB complex and the DNA Internal Control, < 0.01% Oligonucleotide aptamer	17.5 mL

Table 2 cobas® MTB Positive Control Kit

cobas® MTB Positive Control Kit

Store at 2-8°C

For use on the **cobas®** 5800 system, and the **cobas®** 6800/8800 systems with software version 2.0 or higher (P/N 09040587190)

For use on the **cobas®** 6800/8800 systems with software version 1.4 (P/N 07544812190 or P/N 09040587190)

Kit components	Reagent ingredients	Quantity per kit
MTB Positive Control (MTB (+) C)	Tris buffer, < 0.05% sodium azide, < 0.05% EDTA, 0.002% Poly rA, <0.01% Non-infectious plasmid DNA (microbial) containing M. tuberculosis genomic sequence	16 mL (16 x 1mL)

Table 3 cobas® Buffer Negative Control Kit

cobas® Buffer Negative Control Kit

Store at 2-8°C

For use on the **cobas®** 5800 system, and the **cobas®** 6800/8800 systems with software version 2.0 or higher (P/N 09051953190)

For use on the **cobas®** 6800/8800 systems with software version 1.4 (P/N 07002238190 or P/N 09051953190)

Kit components	Reagent ingredients	Quantity per kit
cobas® Buffer Negative Control (BUF (-) C)	Tris buffer, < 0.1% sodium azide, EDTA, 0.002% Poly rA RNA (synthetic)	16 mL (16 x 1mL)

cobas® omni reagents for sample preparation

Table 4 cobas® omni reagents for sample preparation

Reagents	Reagent ingredients	Quantity per kit	Safety symbol and warning*
cobas® omni MGP Reagent (MGP) Store at 2-8°C (P/N 06997546190)	Magnetic glass particles, Tris buffer, 0.1% methyl-4 hydroxybenzoate, < 0.1% sodium azide	480 tests	Not applicable
cobas® omni Specimen Diluent (SPEC DIL) Store at 2-8°C (P/N 06997511190)	Tris buffer, 0.1% methyl-4 hydroxybenzoate, < 0.1% sodium azide	4 x 875 mL	Not applicable
cobas® omni Lysis Reagent (LYS) Store at 2-8°C (P/N 06997538190)	43% (w/w) guanidine thiocyanate**, 5% (w/v) polydocanol**, 2% (w/v) dithiothreitol**, dihydro sodium citrate	4 x 875 mL	 **DANGER** H302: Harmful if swallowed. H314: Causes severe skin burns and eye damage. H411: Toxic to aquatic life with long lasting effects. EUH032: Contact with acids liberates very toxic gas. EUH071 Corrosive to the respiratory tract. P273: Avoid release to the environment. P280: Wear protective gloves/protective clothing/eye protection/face protection/ hearing protection. P303 + P361 + P353: IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water. P304 + P340 + P310: IF INHALED: Remove person to fresh air and keep comfortable for breathing. Immediately call a POISON CENTER/doctor. P305 + P351 + P338 + P310: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/doctor. P391 Collect spillage. 593-84-0 Guanidinium thiocyanate 9002-92-0 Polidocanol 3483-12-3 (R*,R*)-1,4-dimercaptobutane-2,3-diol
cobas® omni Wash Reagent (WASH) Store at 15-30°C (P/N 06997503190)	Sodium citrate dihydrate, 0.1% methyl-4 hydroxybenzoate	4.2 L	Not applicable

* Product safety labeling primarily follows EU GHS guidance

** Hazardous substance or mixture.

Reagent storage requirements

Reagents must be stored and handled as specified in Table 5, Table 6 and Table 7.

When reagents are not loaded on the **cobas**® 5800 or **cobas**® 6800/8800 systems, store them at the corresponding temperature specified in Table 5.

Table 5 Reagent storage (when reagent is not on the system)

Reagent	Storage temperature
cobas® MTB	2-8°C
cobas® MTB Positive Control Kit	2-8°C
cobas® Buffer Negative Control Kit	2-8°C
cobas® **omni** Lysis Reagent	2-8°C
cobas® **omni** MGP Reagent	2-8°C
cobas® **omni** Specimen Diluent	2-8°C
cobas® **omni** Wash Reagent	15-30°C

Reagent handling requirements for the cobas® 5800 system or cobas® 6800/8800 systems

Reagents loaded onto the **cobas**® 5800 system or **cobas**® 6800/8800 systems are stored at appropriate temperatures their expiration is monitored and enforced by the system. The system allows reagents to be used only if all of the reagent handling conditions shown in Table 6, Table 7 and Table 8 are met. The system automatically prevents use of expired reagents. Remaining open-kit stability and number of kit uses information for assay specific reagents is accessible through the system user interface.

Table 6 Reagent expiry conditions monitored and enforced by the **cobas**® 5800 system

Reagent	Open-kit stability	Number of kit uses	On-board stability
cobas® MTB	90 days from first usage	40	36 days from loading
cobas® MTB Positive Control Kit	single vial use	16	36 days from loading
cobas® Buffer Negative Control Kit	single vial use	16	36 days from loading

Table 7 Reagent expiry conditions monitored and enforced by the **cobas**® 6800/8800 systems

Reagent	Open-kit stability	Number of kit uses	On-board stability (outside on board refrigerator)
cobas® MTB	90 days from first usage	40	40 hours
cobas® MTB Positive Control Kit	single vail use	16	10 hours
cobas® Buffer Negative Control Kit	single vial use	16	10 hours

Table 8 shows the open-kit stability of the **cobas**® o**mni** reagents. Prior to each run, the system verifies the open-kit stability and ensures sufficient fill volume. Therefore, these reagents have no number of kit uses or on-board stability assigned.

Table 8 **cobas**® **omni** reagent expiry condition enforced by the **cobas**® 5800/6800/8800 systems

Reagent	Open-kit stability
cobas® **omni** Lysis Reagent	30 days from loading
cobas® **omni** MGP Reagent	30 days from first usage
cobas ®**omni** Specimen Diluent	30 days from loading
cobas® **omni** Wash Reagent	30 days from loading

Additional materials required for the cobas® 5800/6800/8800 systems

Table 9 Materials for use on the **cobas**® 5800/6800/8800 systems

Material	P/N
cobas® **omni** Lysis Reagent	06997538190
cobas® **omni** MGP Reagent	06997546190
cobas® **omni** Specimen Diluent	06997511190
cobas® **omni** Wash Reagent	06997503190

Table 10 Consumables for use on the **cobas**® 5800 system*

Material
cobas® **omni** Processing Plate 24
cobas® **omni** Amplification Plate 24
cobas® **omni** Liquid Waste Plate 24
cobas® **omni** Liquid Waste Container
Tip CORE TIPS with Filter, 1ml
Tip CORE TIPS with Filter, 300µL
Solid Waste Bag*or Solid Waste Bag With insert
16-position tube S-carrier complete
5-position Rack Carrier

* For Part Numbers please refer to the **cobas**® 5800 system User Assistance.

Table 11 Consumables for use on **cobas**® 6800/8800 systems*

Material
cobas® **omni** Processing Plate
cobas® **omni** Amplification Plate
cobas® **omni** Pipette Tips
cobas® **omni** Liquid Waste Container
Solid Waste Bag and Solid Waste Container or Solid Waste Bag With Insert and Kit Drawer
STD-Rack. re-run R001-R025 PINK

* For Part Numbers please refer to the **cobas**® 6800/8800 systems User Assistance

Table 12 Other materials and consumables required for pre-analytic workflow

Materials
cobas® Microbial Inactivation Solution (P/N 08185476001)
Tube sonicator TS 5 (Rinco Ultrasonics AG - P/N 46690)
5 mL polypropylene screw cap tubes 75x13mm, round base (Sarstedt - Tube P/N 60.504.010, Screw cap P/N 65.163)*
MPA RACK 13 MM LIGHT GREEN 7001-7050 (Roche - P/N 03118878001 or equivalent)**
Centrifuge (Option to restrict RCF to max. 3000 x g, compatible with 75x13mm screw-cap tubes)
Vortex mixer
Thermostable barcode labels (OPAL Associates AG, P/N 20300824 TTR PE-Folie Pharma or equivalent)***

*Use of tubes other than those recommended above must be verified by user prior to implementation into **cobas**® MTB workflow in the laboratory.

** MPA 13mm racks are required to run the tube sonicator TS 5. Contact your local Roche representative for a detailed order list for equivalent sample racks in other colors or number ranges. Note that RD5 racks are not compatible with the tube sonicator TS 5.

***For further details on barcode specifications refer to the **cobas**® 5800/6800/8800 systems - User Assistance. Use of barcode labels other than those recommended above must be verified by user prior to implementation into **cobas**® MTB workflow in the laboratory. Contact your local Roche representative for further details on compatible barcode labels and suggestions for compatibility verification. The use of non-compatible barcode labels may lead to tube damage during sonication and subsequent contamination of instrument.

Instrumentation and software required

The **cobas**® 5800 software, the **cobas**® 6800/8800 systems software and **cobas**® MTB analysis package for the **cobas**® 5800/6800/8800 systems must be installed.

For **cobas**® 5800 and the **cobas**® 6800/8800 systems software version 2.0 or higher, the x800 Data Manager software and PC (or server) will be provided with the system.

For the **cobas**® 6800/8800 systems with software version 1.4, the Instrument Gateway (IG) server will be provided with the system.

Table 13 Instrumentation

Equipment	**P/N**
cobas® 5800 system	08707464001
cobas® 6800 system	05524245001 and 09575154001
cobas® 8800 system	05412722001 and 09575154001
Sample Supply Module for **cobas**® 6800/8800 systems	06301037001 and 09936882001

Refer to the **cobas**® 5800 system or **cobas**® 6800/8800 systems – User Assistance for additional information.

Precautions and handling requirements

Warnings and precautions

As with any test procedure, good laboratory practice is essential to the proper performance of this assay. Due to the high sensitivity of this test, care should be taken to keep reagents and amplification mixtures free of contamination.

- For in vitro diagnostic use only.
- All patient samples should be considered potentially infectious. Therefore, all biological specimens should be handled as if infectious, using good laboratory procedures and adequate risk assessment as outlined in Biosafety in Microbiological and Biomedical Laboratories, in the CLSI Document M29-A4 and in the Tuberculosis Laboratory Biosafety Manual by WHO.[12-14] Only personnel proficient in handling infectious materials and the use of **cobas**® MTB and **cobas**® 5800/6800/8800 systems should perform this procedure.
- All personnel should wear protective personal equipment, including laboratory coats, disposable gloves, and eye and respiratory protection according to their institutions safety procedures and practices and should follow their institution's safety procedures for working with chemicals and biological specimens.
- Each laboratory must determine the necessary specimen handling steps before and after MIS inactivation based on an adequate risk assessment and must adhere to recommended biosafety regulations, local and institutional guidelines or regulations and based on an adequate risk assessment.[14]
- Success in TB inactivation depends on adherence to procedures outlined in this document and complete mixing of sample with MIS. Specimen liquefaction and mycobacterial inactivation by MIS should be performed in line with local and institutional guidelines or regulations and based on an adequate risk assessment.
- All human-sourced materials should be considered potentially infectious and should be handled with universal precautions. If spillage occurs, immediately disinfect with a freshly prepared solution of 0.5% sodium or potassium hypochlorite in distilled or deionized water or follow appropriate site procedures.
- **If spillage of samples in MIS (which contains guanidinium thiocyanate) occurs, do not allow it to come in contact with sodium or potassium hypochlorite. This mixture can produce a highly toxic gas.** If spillage of samples in MIS occurs, FIRST clean with a suitable laboratory detergent and water, and then with 70% ethanol.
- MIS is light-sensitive and shipped in light-protective bottles. MIS must be stored upright.
- Use only supplied or specified required consumables to ensure established test performance.
- Closely follow procedures and guidelines provided to ensure that the test is performed correctly. Any deviation from the procedures and guidelines may affect established test performance.
- False positive results may occur if carryover contamination of samples is not adequately controlled during sample handling and processing.
- Safety Data Sheets (SDS) are available on request from your local Roche representative.
- Inform your local competent authority and manufacturer about any serious incidents which may occur when using this assay.

Reagent handling

- Handle all reagents, controls, and samples according to good laboratory practice in order to prevent carryover of samples, reagents, or controls.
- Before use, visually inspect each reagent cassette, diluent, lysis reagent, and wash reagent to ensure that there are no signs of leakage. If there is any evidence of leakage, do not use that material for testing.
- **cobas**® **omni** Lysis Reagent and MIS contain guanidium thiocyanate, a potentially hazardous chemical. Avoid contact of reagents with the skin, eyes, or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, burns can occur.
- Do not allow **cobas**® **omni** Lysis Reagent or MIS, which contain guanidium thiocyanate, to contact sodium or potassium hypochlorite solution. This mixture can produce a highly toxic gas.
- Expended control kits contain pierced vials with residual reagent; special care should be taken during disposal to avoid spills and contact.
- **cobas**® MTB, **cobas**® MTB Positive Control Kit, **cobas**® Buffer Negative Control Kit, **cobas**® **omni** MGP Reagent, and **cobas**® **omni** Specimen Diluent contain sodium azide as a preservative. Avoid contact of reagents with the skin, eyes, or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, burns can occur. If these reagents are spilled, dilute with water before wiping dry.
- Dispose of all materials that have come in contact with samples and reagents in accordance with country, state, and local regulations.

Good laboratory practice

- Do not pipette by mouth.
- Do not eat, drink, or smoke in designated work areas.
- Treat all biological specimens, including MIS treated samples, as if capable of transmitting infectious agents according to local and institutional guidelines or regulations and/or based on an adequate risk assessment.[14] Wear laboratory gloves, laboratory coats, and eye and respiratory protection when handling samples and reagents according to institutional guidelines. Avoid contaminating gloves when handling samples and controls. Gloves must be changed between handling samples and **cobas**® MTB, **cobas**® MTB Positive Control Kit, **cobas**® Buffer Negative Control Kit**,** and **cobas**® **omni** reagents to prevent contamination.
- Disinfect and wash hands thoroughly after handling samples and reagents, and after removing the gloves.
- Thoroughly clean and disinfect all laboratory work surfaces with a freshly prepared solution of 0.5% sodium or potassium hypochlorite in distilled or deionized water. Follow by wiping the surface with 70% ethanol.
- If spills occur on the **cobas**® 5800/6800/8800 systems, follow the instructions in the **cobas**® 5800 or **cobas**® 6800/8800 systems User Assistance to properly clean and decontaminate the surface(s) of instrument(s).

Specimen collection, transport, and storage

Note: Handle all samples and controls as if they are capable of transmitting infectious agents.

Specimens

Raw sputum and NALC-NaOH-treated sputum and BAL sediments may be used with **cobas**® MTB.

Specimen transport and storage

Raw sputum specimens may be stored and/or transported for up to 3 days at 2°C to 35°C, followed by up to 7 days at 2°C to 8°C prior to sample liquefaction and inactivation by MIS. For long-term storage of MIS untreated raw sputum specimens, temperatures at ≤ -20°C are recommended.

NALC-NaOH-treated sputum and BAL sediment specimens may be stored for up to 7 days at 2°C to 8°C prior to sample inactivation by MIS. For long-term storage of MIS untreated sputum and BAL sediments, specimens may be stored frozen at temperatures ≤ -20°C for up to 9 months including two freeze/thaw cycles.

If samples are to be shipped, they should be packaged and labeled in compliance with applicable country and/or international regulations covering the transport of infectious samples and etiologic agents.

Inactivated specimen storage

Raw sputum and NALC-NaOH-treated sputum and BAL sediment specimens treated with MIS (inactivated) may be stored for up to 12 hours at 15°C to 35°C, followed by up to 7 days at 2°C to 8°C and 30 days at ≤ -20°C including two freeze/thaw cycles prior to processing on the **cobas**® 5800/6800/8800 systems.

Note: MIS-treated specimens may not freeze due to high isopropanol content.

Note: Sonication of specimens may be performed at any time after an initial incubation with MIS for a minimum of 60 minutes. Refer to the “Sonication of specimens” section for more details.

Instructions for use

Procedural notes

- Do not use **cobas**® MTB, **cobas**® MTB Positive Control Kit, **cobas**® Buffer Negative Control Kit, MIS or **cobas**® **omni** reagents after their expiry dates.
- Do not reuse consumables. They are for one-time use only.
- **cobas**® MTB can be run with a minimum sample volume of 1.2 mL of which 850 µL is processed.
- Ensure that thermostable barcode labels on sample tubes are oriented towards and visible through the slits open at the top on the side of MPA sample racks. Refer to Figure 1 and to the **cobas**® 5800/6800/8800 systems - User Assistance for proper barcode specifications and additional information on loading sample tubes.
- Ensure that sample tubes are uncapped after sonication and before loading on the **cobas**® 5800/6800/8800 systems.
- Refer to the **cobas**® 5800/6800/8800 systems - User Assistance for proper maintenance of instruments.

Prior to running **cobas**® MTB on the **cobas**® 5800/6800/8800 systems, specimens must be processed according to the following sections: “Processing of raw sputum specimens” or “Processing of sputum and BAL sediments”, and “Sonication of specimens”. Abbreviated representative workflows are summarized in Table 14 for the raw sputum specimen type and in Table 15 for the sediment specimen type. For further details refer to the subsequent sections.

> ***Note:*** Specimen handling before and after **cobas**® MIS inactivation should be performed according to local and institutional guidelines or regulations and/or based on an adequate risk assessment.[14]
>
> ***Note:*** Sonication of MIS-treated specimens should be performed according to local and institutional guidelines or regulations and/or based on an adequate risk assessment.[14]

Table 14 Workflow overview - Raw sputum specimen type

1		 	Add 2 parts of MIS to 1 part of raw sputum
2		30-60 seconds	Shake vigorously or vortex for 30-60 seconds
3		≥ 60 minutes	Incubate sample for at least 60 min at 15-30°C (room temperature)
4		30-60 seconds	Shake vigorously or vortex for 30-60 seconds
5		1.2 mL for 1 test 2.4 mL for 2 tests 3.6 mL for 3 tests	Transfer 1.2 to 3.6 mL of MIS-treated sample to screw cap secondary tube
6		5 minutes	Sonicate MIS-treated sample
7		Max. 1 minute	Centrifuge sample for no more than 1 minute at maximal RCF of 3000 x g
8			Load uncapped sample on **cobas**® 5800 or **cobas**® 6800/8800 systems and start run using the raw sputum specimen type

Table 15 Workflow overview - Sediment specimen type

1		0.2 mL for 1 test 0.4 mL for 2 tests 0.6 mL for 3 tests	Vortex and transfer 0.2 to 0.6 mL of sediment sample to screw cap secondary tube
2		 	Add 5 parts of MIS to 1 part of sediment sample • 1 mL MIS for 1 test (0.2 mL sediment sample) • 2 mL MIS for 2 tests (0.4 mL sediment sample) • 3 mL MIS for 3 tests (0.6 mL sediment sample)
3		30-60 seconds	Shake vigorously or vortex for 30-60 seconds
4		≥ 60 minutes	Incubate sample for at least 60 min at 15-30°C (room temperature)
5		30-60 seconds	Shake vigorously or vortex for 30-60 seconds
6		5 minutes	Sonicate MIS-treated sample
7		Max. 1 minute	Centrifuge sample for no more than 1 minute at maximal RCF of 3000 x g
8			Load uncapped sample on **cobas**® 5800 or **cobas**® 6800/8800 systems and start run using the sediment specimen type

Processing of raw sputum specimens

- Confirm that the raw sputum container is properly labeled and contains a minimum of 0.4 mL of sputum. If stored frozen, thaw and equilibrate sample to ambient temperature.
- Invert the MIS bottles two to four times before use.
- Open the sputum container and add approximately two parts of MIS to one part of sputum specimen (e.g., 2 mL of MIS to 1 mL of sputum specimen) by visual volume estimation and using a disposable pipette. Close the sputum container tightly.
- Close the MIS bottles immediately after use.
- Shake vigorously or vortex for 30-60 seconds.

  Note: Ensure that the entire sputum specimen is mixed with MIS.

- Incubate specimen for at least 60 minutes at 15-30°C (room temperature).

  Note: Refer to the "Inactivated specimen storage" section for maximal storage conditions.

- Shake vigorously or vortex for 30-60 seconds or until sample is fully homogenized.
- Transfer a minimum of 1.2 mL and no more than 3.6 mL of MIS-treated sputum specimen into a thermostable barcode labeled 5 mL polypropylene screw-cap tube 75x13mm, round base (Sarstedt - Tube P/N 60.504.010, Cap P/N 65.163). Firmly close the tube.

  Note: Prior to specimen transfer confirm that barcode information on the sputum container and the 5 mL secondary tube match.

  Note: Refer to Table 16.

- Sonicate inactivated specimen according to the "Sonication of specimens" section prior to running **cobas**® MTB.

Processing of sputum and BAL sediments

- Confirm that the NALC-NaOH-treated sputum and BAL sediment container is properly labeled and contains a minimum of 0.2 mL of specimen. If stored frozen, thaw and equilibrate sample to ambient temperature.
- Vortex sediment sample for a minimum of 10 seconds.
- Transfer a minimum of 0.2 mL and no more than 0.6 mL of sediment specimen into a barcode labeled 5 mL polypropylene screw-cap tube 75x13mm, round base (Sarstedt - Tube P/N 60.504.010, Cap P/N 65.163).

  Note: Prior to specimen transfer confirm that barcode information on the specimen container and the 5 mL secondary tube match.

- Invert the MIS bottles two to four times before use.
- Add five parts of MIS to one part of specimen (e.g., 1 mL of MIS to 0.2 mL of specimen). Close the tube tightly.

  Note: Refer to Table 16.

- Close the MIS bottles immediately after use.
- Shake vigorously or vortex for 30-60 seconds.

  Note: Ensure that the entire specimen is mixed with MIS.

- Incubate specimen for at least 60 minutes at 15-30°C (room temperature).

  Note: Refer to the "Inactivated specimen storage" section for maximal storage conditions.

- Shake vigorously or vortex for 30-60 seconds.
- Sonicate inactivated specimen according to section "Sonication of specimens" prior to running **cobas**® MTB.

Table 16 cobas® Microbial Inactivation Solution-treated specimen volume requirements for running **cobas**® MTB

Number of tests to perform from secondary tube	Minimal volume of MIS-treated specimen required	Maximal volume of MIS-treated specimen allowed
1 test order	1.2 mL	3.6 mL
2 test orders*	2.4 mL	3.6 mL
3 test orders*	3.6 mL	3.6 mL

* May be used for processing in mixed-batch with other **cobas**® 5800/6800/8800 assays using the same specimen type or for repeat testing.

Sonication of specimens

- Sonication of specimens for running **cobas**® MTB must be performed using the tube sonicator TS 5 device from Rinco Ultrasonics AG (P/N 46690). The use of other sonication devices may lead to false positive, false negative and/or invalid results. The operation of the instrument is described in detail in the manufacturer's User Guide.
- Place five barcode-labeled closed screw-cap tubes containing 1.2 mL to 3.6 mL of MIS-treated specimen into an MPA rack.

  Note: Ensure that thermostable barcode labels on sample tubes are oriented towards and visible through the slits open at the top on the side of MPA sample racks (see Figure 1).

  Note: Ensure that each tube contains one barcode label.

  Note: Ensure that all five tube positions of the MPA rack are occupied. If less than five tubes containing MIS-treated specimen are available, the remaining positions must be occupied with water-filled or MIS-filled "dummy" tubes of the same tube type and with a barcode label.

Figure 1 Correct placement of sample tubes in MPA rack prior to sonication

- Start the tube sonicator.
- Select the predefined sonication profile “Respiratory Samples”.
- Open the tube sonicator device and insert the MPA rack according to the manufacturer’s instructions.
- Close the tube sonicator.
- Start the sonication run.
- Confirm that the sonication run was successful and remove the MPA rack.

  Note: Sample tubes are expected to warm up during the sonication run. Exercise caution when removing the MPA rack with sample tubes.

  Note: In case of a sonication failure, refer to the manufacturer’s instructions, correct the cause and repeat the sonication run after allowing the samples to cool down for at least 15 min.
- MIS-treated and sonicated specimens may now be run with **cobas**® MTB or may be stored according to the “Inactivated specimen storage” section.

Running cobas® MTB on the cobas® 5800/6800/8800 systems

- The operation of the instruments is described in detail in the **cobas**® 5800 system or **cobas**® 6800/8800 systems User Assistance.
- Refer to the **cobas**® 5800 system or **cobas**® 6800/8800 systems User Assistance for proper maintenance of instruments
- Prior to uncapping tubes and loading specimens onto the **cobas**® 5800 system, it is recommended to pellet cell and matrix debris by specimen centrifugation for a maximum of 1 minute at a maximum RCF of 3000 x g.
- A single run can have a combination of specimens (raw sputum, sediment).
- Ensure that specimen barcode labels on sample tubes are visible through the openings on the side of RD5 or MPA sample racks. Refer to the **cobas**® 5800 system or **cobas**® 6800/8800 systems User Assistance for proper barcode specifications and additional information on loading sample tubes.

Note: Vortex specimens for a minimum of 10 seconds if specimens have been stored for more than 1 hour after sonication and before centrifugation.

Note: The omission of the centrifugation step may result in an increased rate of sample clots on the **cobas**® 5800 system.

Figure 2 **cobas**® MTB test procedure on the **cobas**® 5800 system



Figure 3 **cobas**® MTB test procedure on the **cobas**® 6800/8800 systems

1	Log onto the system Press Start to Prepare the system Order Tests • Choose “Raw sputum” for ordering MIS-treated raw sputum specimens • Choose “Sediment” for ordering MIS-treated sputum/BAL sediment specimens
2	Refill reagents and consumables as prompted by the system • Load test specific reagent cassette • Load control cassettes • Load Pipette Tips • Load Processing Plates • Load MGP Reagent • Load Amplification Plates • Refill Specimen Diluent • Refill Lysis Reagent • Refill Wash Reagent

3	Loading specimens onto the system
	• For each specimen
	  ○ Uncap tube
	  ○ Transfer tube to rack
	• Load sample rack and clot tip racks into the sample supply module
	• Confirm samples have been accepted into the transfer module

4	Start run
5	Review and export results
6	Remove and cap any sample tubes meeting the minimum volume requirements if needed for future use Clean up instrument • Unload empty control cassettes • Empty amplification plate drawer • Empty liquid waste • Empty solid waste

Results

cobas® MTB automatically detects MTB complex DNA for samples and controls, displaying test validity, as well as individual target results.

Quality control and validity of results on the cobas® 5800 system and cobas® 6800/8800 systems with software version 2.0 or higher

- One **cobas**® Buffer Negative Control [(-) Ctrl] and one **cobas**® MTB Positive Control [MTB (+) C] are processed at least every 72 hours and with every new kit lot. Positive and/or negative controls can be scheduled more frequently based on laboratory procedures and/or local regulations.
- In the software and/or report, check for flags and their associated results to ensure the result validity (refer to the x800 Data Manager User Assistance for a 'List of flag codes').
- Controls are marked with "Valid" in the column "Control result" if the respective target of the controls are reported valid. Controls are marked with "Invalid" in the column "Control result" if the respective target of the controls are reported invalid.
- Controls marked with "Invalid" show a flag in the "Flags" column. More information on why the control is reported invalid including flag information is shown in the detail view
- If one of the controls is invalid, repeat testing of all controls and all associated samples is required.

Validation of results is performed automatically by the instrument software based on control results.

NOTE: The **cobas**® 5800 system and the **cobas**® 6800/8800 systems with version 2.0 or higher will be delivered with the standard setting of running a set of controls (positive and negative) with every run, but can be configured to a less frequent scheduling up to every 72 hours based on laboratory procedures and/or local regulations. Please contact your Roche service engineer and/or Roche customer technical support for more information. .

Quality control and validity of results on the cobas® 6800/8800 systems software version 1.4

- One negative control [(-) Ctrl] and one **cobas**® MTB Positive Control [MTB (+) C] are processed with each batch of a requested result type.
- In the **cobas**® 6800/8800 systems software and/or report, check for flags and their associated results to ensure batch validity.
- All flags are described in the **cobas**® 6800/8800 systems - User Assistance.
- The batch is valid if no flags appear for all controls. If the batch is invalid, repeat testing of the entire batch iss required.

Validation of batch results is performed automatically by the instrument software based on control results,

Interpretation of results for cobas® 5800/6800/8800 systems

Results and their corresponding interpretation for detecting MTB are shown in Table 17.

Table 17 cobas® MTB results and interpretation

Target 1	Interpretation
MTB Positive	The requested result was valid. Target signal detected for *M. tuberculosis* complex DNA.
MTB Negative	The requested result was valid. No target signal detected for *M. tuberculosis* complex DNA.
Invalid	MTB result is invalid. Original specimen should be re-tested to obtain valid MTB results. If the result is still invalid and an instrument error can be excluded, a new specimen should be obtained.

Interpretation of results for cobas® 5800 system and cobas® 6800/8800 systems with software version 2.0 or higher

The results of the samples are shown in the "Results" app of the software. Result display examples are shown in Table 17.

For a valid control batch, check each individual sample for flags in the software and/or report. The result interpretation should be as follows:

- Samples associated with a valid control batch are shown as 'Valid' in the "Control result" column if the respective control target results reported valid. Samples associated with a failed control batch are shown as 'Invalid' in the

  "Control result" column if all control target results reported invalid.
- If the associated controls of a sample result are invalid, a specific flag will be added to the sample result as follows:
  - Q05D : Result validation failure because of an invalid positive control
  - Q06D :Result validation failure because of an invalid negative control
- The values in "Results" column for individual sample target result should be interpreted as shown in Table 17 above.
- If one or more sample targets are marked with "Invalid" the software shows a flag in the "Flags"column. More information on why the sample target(s) is reported invalid including flag information is shown in the detail view.

Figure 4 Example of **cobas**® MTB results on the **cobas**® 5800 system and **cobas**® 6800/8800 systems with software version 2.0

Sample ID	Test	Control result	Flag	Status	Result	Creation date/time
MTB_S_pos_02	MTB	Valid		Released	**MTB Positive (Ct 37.99)**	5/12/2022 3:44:55 PM
MTB_S_pos_01	MTB	Valid		Released	**MTB Positive (Ct 38.76)**	5/12/2022 3:44:55 PM
MTB_S_neg_02	MTB	Valid		Released	MTB Negative	5/12/2022 3:44:56 PM
MTB_S_neg_01	MTB	Valid		Released	MTB Negative	5/12/2022 3:44:56 PM
MTB_S_inv_01	MTB	Valid	⚑	Released	**MTB Invalid**	5/12/2022 1:41:06 PM
MTB_RS_pos_02	MTB	Valid		Released	**MTB Positive (Ct 39.32)**	5/12/2022 3:44:54 PM
MTB_RS_pos_01	MTB	Valid		Released	**MTB Positive (Ct 39.53)**	5/12/2022 3:44:54 PM

Interpretation of results for cobas® 6800/8800 systems with software version 1.4

For a valid batch, check each individual sample for flags in the **cobas**® 6800/8800 systems software and/or report. The result interpretation should be as follows:

- A valid batch may include both valid and invalid sample results.
- The "Valid" and "Overall Result" columns are not applicable (NA) to sample results for the **cobas**® MTB and are marked with "NA". Values reported in these columns are not applicable and **do not** impact the validity of results reported within individual Target Result columns.
- Reported target results for individual samples are valid unless indicated as "Invalid" within the individual target result column.
- Results of this test should only be interpreted in conjunction with information available from clinical evaluation of the patient and patient history.

Figure 5 Example of **cobas**® MTB results on the **cobas**® 6800/8800 systems software version 1.4

Test	Sample ID	Valid	Flags	Sample type	Overall result	Target 1
MTB	TB_R_0001	NA		Raw sputum	**NA**	MTB Negative
MTB	TB_R_0002	NA		Raw sputum	**NA**	MTB Positive
MTB	TB_R_0003	NA	P02T	Raw sputum	**NA**	Invalid
MTB	TB_S_0001	NA		Sediment	**NA**	MTB Negative
MTB	TB_S_0002	NA		Sediment	**NA**	MTB Positive
MTB	TB_S_0003	NA	C02H1	Sediment	**NA**	Invalid
MTB	C161420284090428828404	Yes		(-) Ctrl	**Valid**	Valid
MTB	C161420284093009580264	Yes		MTB (+) C	**Valid**	Valid

Procedural limitations

- **cobas**® MTB should always be performed along with mycobacterial culture to minimize the risk of false negative results, as well as to allow for drug susceptibility testing of the MTBC isolate to aid in patient management.
- The performance of **cobas**® MTB has been validated for raw sputum and for sputum and BAL sediment specimens that have been liquefied, decontaminated and concentrated using NALC-NaOH. The use of other sample types may lead to false positive, false negative and/or invalid results.
- Digestion and decontamination should be performed using NALC-NaOH procedures recommended by the CDC.[15] The use of alternative pre-analytic sample preparation procedures may lead to false positive, false negative and/or invalid results.
- **cobas**® MTB has been validated for use with raw sputum and NALC-NaOH-treated sputum and BAL sediment specimens chemically inactivated using MIS. Other inactivation procedures have not been evaluated and may lead to false positive, false negative and/or invalid results.
- Success in TB inactivation depends on adherence to procedures outlined in this document and complete mixing of sample with MIS. Specimen liquefaction and mycobacterial inactivation by MIS should be performed in line with local and institutional guidelines or regulations and based on an adequate risk assessment.

- Exceeding volume limitations and/or deviating from the procedural steps outlined in "Processing of raw sputum specimens", "Processing of sputum and BAL sediments" and "Sonication of specimens" sections may lead to false positive, false negative and/or invalid results.
- Nucleic Acid Amplification assays are unable to determine viability of organism.
- Therapeutic success or failure cannot be determined using this test.
- Use of this product must be limited to personnel trained in the techniques of PCR and the use of the **cobas**® 5800/6800/8800 systems.
- **cobas**® MTB has been evaluated only for use in combination with the **cobas**® MTB Positive Control Kit, **cobas**® Buffer Negative Control Kit, **cobas**® **omni** MGP Reagent, **cobas**® **omni** Lysis Reagent, **cobas**® **omni** Specimen Diluent, and **cobas**® **omni** Wash Reagent for use on the **cobas**® 5800/6800/8800 systems, the MIS, and the tube sonicator TS 5 from Rinco Ultrasonics AG.
- Reliable results depend on proper sample collection, storage, and handling procedures.
- **cobas**® MTB is not indicated for use with respiratory specimens for monitoring treatment response or as a test for cure.
- **cobas**® MTB does not distinguish between the various species of the MTB-complex and between viable and non-viable organisms.
- Detection of M. tuberculosis is dependent on the number of organisms present in the specimen and may be affected by specimen collection methods, and patient factors (i.e., age, severity of disease, HIV status).
- For patients who are both MTB and HIV infected, there is a higher likelihood of specimens being smear microscopy negative and therefore having MTB-complex DNA present at levels below the assay's limit of detection.
- Health care providers must interpret results in the context of the patient's history, clinical presentation, as well as other laboratory and radiography test results.
- False negative or invalid results may occur due to polymerase inhibition. The Internal Control is included in **cobas**® MTB to help identify the specimens containing substances that may interfere with nucleic acid isolation and PCR amplification.
- The addition of AmpErase enzyme into the **cobas**® MTB Master Mix reagent enables selective amplification of target DNA; however, good laboratory practices and careful adherence to the procedures specified in this Instructions-For-Use document are necessary to avoid contamination of reagents.
- Though rare, mutations within the highly conserved regions of the genomic DNA of M. tuberculosis complex covered by **cobas**® MTB primers and/or probes may result in failure to detect the presence of the bacterium.
- Due to inherent differences between technologies, it is recommended that, prior to switching from one technology to another, users perform method correlation studies in their laboratory to qualify technology differences. One hundred percent agreement between the results should not be expected due to aforementioned differences between technologies.
- Use of tubes other than those recommended in Table 10 must be verified by user prior to implementation into **cobas**® MTB workflow in the laboratory. Use of other tube types may result in damage to tubes and contamination of sonicator surfaces. False negative results due to insufficient sonication energy transfer may also occur.
- Use of barcodes other than those recommended in Table 10 must be verified by user prior to implementation into **cobas**® MTB workflow in the laboratory. Use of other barcode types may result in damage to the barcode.

Performance evaluation

System equivalency

System equivalency of the **cobas**® 5800, **cobas**® 6800 and **cobas**® 8800 systems was demonstrated via performance studies. The data presented in this Instructions for Use support equivalent performance for all systems.

Key performance characteristics

Sample inactivation

The reduction of MTB infection risk by treating samples with MIS was evaluated using high positive cultures of two MTB complex strains (MTB CDC268 and MTB H37) at three different sites and using three different MIS reagent lots. For each condition five culture aliquots of concentration levels up to 5 x 10^7 CFU/mL were treated with MIS in a 1:2 ratio for 60 minutes at room temperature. The samples were then centrifuged for 15 minutes at 3000 x g, washed twice with sterile PBS and finally resuspended in 0.5mL of sterile PBS. At two sites, the entire inactivated sample was inoculated and tested for growth using the BACTEC™ MGIT™ 320 Mycobacterial Detection System (Becton Dickinson). At the third site, MTB viability was tested on solid Löwenstein-Jensen (LJ) medium. None of the inactivated samples showed growth of M. tuberculosis complex bacteria at the end of the 56-day incubation period.

Limit of Detection (LoD)

The limit of detection of **cobas**® MTB was determined by analysis of serial dilutions of two MTB complex strains (M. tuberculosis CDC268 and M. bovis BCG 1st WHO Reference Reagent for BCG vaccine of Danish 1331 sub-strain) each in two pooled negative clinical matrices - raw sputum and sputum/BAL sediments. Panels of seven to nine concentration levels plus a blank were tested by a total of 72 replicates per concentration level using three lots of **cobas**® MTB test reagents over multiple runs, days, operators, and instruments.

The LoD for *M. tuberculosis* ranged from 7.6 CFU/mL (sputum/BAL sediment) to 8.8 CFU/mL (raw sputum).

The LoD for *M. bovis* BCG ranged from 0.9 CFU/mL (sputum/BAL sediment) to 1.0 CFU/mL (raw sputum).

Inclusivity

The inclusivity of **cobas**® MTB for ten members of the MTB complex was confirmed by testing of the following 22 strains:

- *M. tuberculosis* (H37 ATCC®-25177™, TB-TDR-0032, TB-TDR-0039, TB-TDR-0105, TB-TDR-0114, TB-TDR-0115, TB-TDR-0116, TB-TDR-0131, TB-TDR-0144, TB-TDR-0185, TB-TDR-0198, 80552)
- *M. bovis BCG* (substrain Tokyo 172 NIBSC 07/270 WHO, substrain Moscow NIBSC 07/274 WHO)
- *M. africanum* (ATCC® 25420™)
- *M. bovis* subsp. *bovis* (ATCC® 19210™)
- *M. canetti* (NLA 000016778)
- *M. caprae* (ATCC® BAA-824™)
- *M. microti* (ATCC® 19422™)
- *M. orygis* (NLA 001300863)
- *M. pinnipedii* (ATCC® BAA-688™)
- *M. suricattae* (492, Stellenbosch University, Tygerberg, South Africa)

All strains were detected at 28.2 CFU/mL in sediment specimen type. For *M. suricattae* genomic DNA equivalent to 28.2 CFU/mL was tested.

Precision

In-house precision was examined using a panel composed of *M. tuberculosis* (CDC268) and *M. bovis* BCG (1st WHO Reference Reagent for BCG vaccine of Danish 1331 sub-strain) cultures diluted into two pooled negative clinical matrices - raw sputum and sputum/BAL sediments. Sources of variability were examined with a panel consisting of three concentration levels, using three lots of **cobas**® MTB reagents and two instruments over a time course of 12 days and with a total of 24 runs. A description of the precision panels and the observed positivity rates are shown in Table 18. All negative panel members tested negative throughout the study. Analysis of standard deviation and percent coefficient of variation of the Ct values from tests performed on positive panel members (Table 19) yielded overall CV (%) ranging from 1.2% to 2.6% for *M. tuberculosis* and *M. bovis* BCG.

Table 18 Summary of within laboratory precision

Target Concentration	N Tested	N Positive	Positivity Rate	95% Confidence Interval	
				Lower Limit	Upper Limit
M. tuberculosis - raw sputum					
Negative	48	0	0.0%	0.0%	7.4%
8.8 CFU/mL	48	46	95.8%	85.7%	99.5%
26.4 CFU/mL	48	48	100.0%	92.6%	100.0%
M. tuberculosis - sediment					
Negative	48	0	0.0%	0.0%	7.4%
7.6 CFU/mL	48	48	100.0%	92.6%	100.0%
22.8 CFU/mL	48	48	100.0%	92.6%	100.0%
M. bovis BCG - raw sputum					
Negative	48	0	0.0%	0.0%	7.4%
1.0 CFU/mL	48	48	100.0%	92.6%	100.0%
3.0 CFU/mL	48	48	100.0%	92.6%	100.0%
M. bovis BCG – sediment					
Negative	48	0	0.0%	0.0%	7.4%
0.9 CFU/mL	48	45	93.8%	82.8%	98.7%
2.7 CFU/mL	48	48	100.0%	92.6%	100.0%

Table 19 Overall mean, standard deviations and coefficients of variation (%) for cycle threshold, MTBC positive panels

Target Concentration	Positivity Rate	Mean Ct	Within run		Between run		Between day		Between instrument		Between lot		Total	
			SD	CV%	SD	CV%	SD	CV%	SD	CV%	SD	CV%	SD	CV%
M. tuberculosis - raw sputum														
8.8 CFU/mL	95.8%	33.8	0.63	1.9	0.28	0.8	0.43	1.3	0.00	0.0	0.29	0.9	0.86	2.6
26.4 CFU/mL	100.0%	32.4	0.54	1.7	0.07	0.2	0.00	0.0	0.30	0.9	0.00	0.0	0.62	1.9
M. tuberculosis – sediment														
7.6 CFU/mL	100.0%	34.9	0.35	1.0	0.09	0.3	0.14	0.4	0.19	0.5	0.00	0.0	0.43	1.2
22.8 CFU/mL	100.0%	33.9	0.36	1.1	0.22	0.6	0.00	0.0	0.17	0.5	0.06	0.2	0.46	1.4
M. bovis BCG - raw sputum														
1.0 CFU/mL	100.0%	33.5	0.67	2.0	0.00	0.0	0.00	0.0	0.00	0.0	0.22	0.7	0.71	2.1
3.0 CFU/mL	100.0%	32.4	0.40	1.2	0.30	0.9	0.00	0.0	0.00	0.0	0.00	0.0	0.50	1.5
M. bovis BCG – sediment														
0.9 CFU/mL	93.8%	35.1	0.45	1.3	0.00	0.0	0.17	0.5	0.00	0.0	0.17	0.5	0.51	1.5
2.7 CFU/mL	100.0%	34.1	0.39	1.1	0.00	0.0	0.18	0.5	0.00	0.0	0.09	0.3	0.44	1.3

Analytical specificity/cross reactivity

A panel of 178 bacteria, fungi and viruses, including those commonly found in respiratory tract, were tested with **cobas**® MTB to assess analytical specificity. The organisms listed in Table 20 were tested at concentrations of approximately 1 x 10^6 units/mL for bacteria and approximately 1 x 10^5 units/mL for viruses. Testing was performed with each potential interfering organism in absence and presence of MTB complex target (at 200 CFU/mL). None of the organisms interfered with the test performance by generating false positive results. Detection of MTB complex target was not affected by organisms tested. Potential cross-reactivity of *Histoplasma capsulatum*, *Mycobaterium leprae*, *Mycobacterium mantenii* and *Mycobacterium timonense* was evaluated *in silic*o. The results of the *in silico* analyses predict a very low likelihood of amplification and detection of those organisms when using **cobas**® MTB.

Table 20 Microorganisms tested for analytical specificity/cross reactivity

Microorganism	Concentration	Microorganism	Concentration
Acinetobacter baumannii	1.0E+06 CFU/mL	*Mycobacterium gastri*	1.0E+06 CFU/mL
Acinetobacter calcoaceticus	1.0E+06 CFU/mL	*Mycobacterium gordonae*	1.0E+06 CFU/mL
Actinomyces israelii	1.0E+06 CFU/mL	*Mycobacterium haemophilum*	1.0E+06 CFU/mL
Actinomyces odontolyticus	1.0E+06 CFU/mL	*Mycobacterium holsaticum*	1.0E+06 CFU/mL
Adenovirus	1.0E+05 U/mL	*Mycobacterium indicus pranii*	1.0E+06 CFU/mL
Aeromonas hydrophila	1.0E+06 CFU/mL	*Mycobacterium intermedium*	1.0E+06 CFU/mL
Aspergillus fumigatus	1.0E+06 CFU/mL	*Mycobacterium intracellulare*	1.0E+06 CFU/mL
Bacillus cereus	1.0E+06 CFU/mL	*Mycobacterium kansasii*	1.0E+06 CFU/mL
Bacillus subtilis subsp. *subtilis*	1.0E+06 CFU/mL	*Mycobacterium kumamontonense*	1.0E+06 CFU/mL
Bactericides fragilis	1.0E+06 CFU/mL	*Mycobacterium lentiflavum*	1.0E+06 CFU/mL
Blastomyces dermatitidis	1.0E+06 geq/mL	*Mycobacterium malmoense*	1.0E+06 CFU/mL
Bordetella parapertussis	1.0E+06 CFU/mL	*Mycobacterium marinum*	1.0E+06 CFU/mL
Bordetella pertussis	1.0E+06 CFU/mL	*Mycobacterium marseillense*	1.0E+06 CFU/mL
Burkholderia cepacia	1.0E+06 CFU/mL	*Mycobacterium mucogenicum*	1.0E+06 CFU/mL

Microorganism	Concentration	Microorganism	Concentration
Campylobacter jejuni subsp. *jejuni*	1.0E+06 CFU/mL	*Mycobacterium neoaurum*	1.0E+06 CFU/mL
Candida albicans	1.0E+06 CFU/mL	*Mycobacterium nonchromogeicum*	1.0E+06 CFU/mL
Candida glabrata	1.0E+06 CFU/mL	*Mycobacterium peregrinum*	1.0E+06 CFU/mL
Candida krusei	1.0E+06 CFU/mL	*Mycobacterium scrofulaceum*	1.0E+06 CFU/mL
Candida parapsilosis	1.0E+06 CFU/mL	*Mycobacterium simiae*	1.0E+06 CFU/mL
Candida tropicalis	1.0E+06 CFU/mL	*Mycobacterium smegmatis*	1.0E+06 CFU/mL
Chlamydia trachomatis	1.0E+06 IFU/mL	*Mycobacterium szulgai*	1.0E+06 CFU/mL
Chlamydophila pneumoniaea	1.0E+06 IFU/mL	*Mycobacterium terrae*	1.0E+06 CFU/mL
Chromobacterium violaceum	1.0E+06 CFU/mL	*Mycobacterium thermoresistible*	1.0E+06 CFU/mL
Citrobacter freundii	1.0E+06 CFU/mL	*Mycobacterium triviale*	1.0E+06 CFU/mL
Clostridium perfringens	1.0E+06 CFU/mL	*Mycobacterium vaccae*	1.0E+06 CFU/mL
Corynebacterium diphtheriae	1.0E+06 CFU/mL	*Mycobacterium vulneris*	1.0E+06 CFU/mL
Corynebacterium jeikeium	1.0E+06 CFU/mL	*Mycobacterium xenopi*	1.0E+06 CFU/mL
Corynebacterium pseudodiptheriticum	1.0E+06 CFU/mL	*Mycobacterium yongonense*	1.0E+06 CFU/mL
Corynebacterium ulcerans	1.0E+06 geq/mL	*Mycoplasma pneumoniae*	1.0E+06 ccu/mL
Corynebacterium xerosis	1.0E+06 CFU/mL	*Neisseria gonorrhoeae*	1.0E+06 CFU/mL
Cryptococcus neoformans	1.0E+06 CFU/mL	*Neisseria lactamica*	1.0E+06 CFU/mL
Cytomegalovirus	1.0E+05 IFU/mL	*Neisseria meningitides*	1.0E+06 CFU/mL
Eikenella corrodens	1.0E+06 CFU/mL	*Neisseria mucosa*	1.0E+06 CFU/mL
Enterobacter aerogenes	1.0E+06 CFU/mL	*Neisseria sicca*	1.0E+06 CFU/mL
Enterobacter cloacae subsp. *cloacae*	1.0E+06 CFU/mL	*Nocardia asteroides*	1.0E+06 CFU/mL
Enterococcus avium	1.0E+06 CFU/mL	*Nocardia brasiliensis*	1.0E+06 geq/mL
Enterococcus faecalis	1.0E+06 CFU/mL	*Nocardia cyriacigeorgica*	1.0E+06 CFU/mL
Enterococcus faecium	1.0E+06 CFU/mL	*Nocardia farcinica*	1.0E+06 CFU/mL
Enterovirus Type 68 / 2007	1.0E+05 U/mL	*Nocardia nova*	1.0E+06 CFU/mL
Escherichia coli	1.0E+06 CFU/mL	*Nocardia otitidiscaviarum*	1.0E+06 CFU/mL
Escherichia coli producing CTX-M-15 ESBL	1.0E+06 CFU/mL	*Nocardia transvalensis*	1.0E+06 CFU/mL
Fusobacterium nucleatum subsp. *nucleatum*	1.0E+06 CFU/mL	*Pasteurella multocida* subsp. *tigris*	1.0E+06 CFU/mL
Gordona rubropertinctus	1.0E+06 geq/mL	*Pediococcus acidilactici*	1.0E+06 geq/mL
Haemophilus influenzae	1.0E+06 CFU/mL	*Pediococcus pentosaceus*	1.0E+06 CFU/mL
Haemophilus parahaemolyticus	1.0E+06 CFU/mL	*Penicillium chermesinum*	1.0E+06 CFU/mL
Haemophilus parainfluenzae	1.0E+06 CFU/mL	*Peptostreptococcus anaerobius*	1.0E+06 CFU/mL
Herpes simplex virus Type 1	1.0E+05 cp/mL	*Peptostreptococcus magnus*	1.0E+06 CFU/mL
Herpes simplex virus Type 2	1.0E+05 cp/mL	*Porphyromonas asaccharolytica*	1.0E+06 CFU/mL
Human Immunodeficiency Virus	1.0E+05 cp/mL	*Prevotella melaninogenica*	1.0E+06 CFU/mL
Human influenza virus A	1.0E+05 U/mL	*Propionibacterium acnes*	1.0E+06 CFU/mL
Human influenza virus B	1.0E+05 U/mL	*Proteus mirabilis*	1.0E+06 CFU/mL
Human metapneumovirus	1.0E+05 U/mL	*Proteus vulgaris*	1.0E+06 CFU/mL
Human parainfluenza virus type 1	1.0E+05 U/mL	*Providencia stuartii*	1.0E+06 CFU/mL
Human parainfluenza virus type 2	1.0E+05 U/mL	*Pseudomonas aeruginosa*	1.0E+06 CFU/mL
Human parainfluenza virus type 3	1.0E+05 U/mL	*Rhizopus* spp.	1.0E+06 CFU/mL
Human parainfluenza virus type 4	1.0E+05 U/mL	*Rhodococcus equi*	1.0E+06 CFU/mL
Human respiratory syncytial virus A	1.0E+05 U/mL	Rubella virus	1.0E+05 U/mL
Human respiratory syncytial virus B	1.0E+05 U/mL	Rubeola virus	1.0E+05 U/mL

Microorganism	Concentration	Microorganism	Concentration
Human rhinovirus 16	1.0E+05 U/mL	Rubula virus	1.0E+05 U/mL
Kingella kingae	1.0E+06 CFU/mL	*Salmonella enterica* subsp. *enterica* serovar Dublin	1.0E+06 CFU/mL
Kingella oralis	1.0E+06 CFU/mL	*Scedosporium* spp.	1.0E+06 CFU/mL
Klebsiella oxytoca	1.0E+06 CFU/mL	*Serratia marcescens* subsp. *marcescens*	1.0E+06 CFU/mL
Klebsiella pneumoniae producing KPC-3	1.0E+06 CFU/mL	*Shigella flexneri*	1.0E+06 CFU/mL
Klebsiella pneumoniae subsp. *pneumoniae*	1.0E+06 CFU/mL	*Shigella sonnei*	1.0E+06 CFU/mL
Lactobacillus acidophilus	1.0E+06 CFU/mL	*Staphylococcus aureus* subsp. *aureus*	1.0E+06 CFU/mL
Lactobacillus casei	1.0E+06 CFU/mL	*Staphylococcus capitis* subsp. *capitis*	1.0E+06 CFU/mL
Legionella micdadei	1.0E+06 CFU/mL	*Staphylococcus epidermidis*	1.0E+06 CFU/mL
Legionella pneumophila subsp.*pneumophila*	1.0E+06 CFU/mL	*Staphylococcus haemolyticus*	1.0E+06 CFU/mL
Leuconostoc mesenteroides subsp.	1.0E+06 CFU/mL	*Staphylococcus hominis* subsp. *hominis*	1.0E+06 CFU/mL
Listeria monocytogenes	1.0E+06 CFU/mL	*Staphylococcus lugdunensis*	1.0E+06 CFU/mL
Moraxella catarrhalis	1.0E+06 CFU/mL	*Stenotrophomonas maltophilia*	1.0E+06 CFU/mL
Morganella morganii subsp. *morganii*	1.0E+06 CFU/mL	*Streptococcus agalactiae*	1.0E+06 CFU/mL
Mycobacterium abscessus	1.0E+06 CFU/mL	*Streptococcus constellatus* subsp. *constellatus*	1.0E+06 CFU/mL
Mycobacterium arosiense	1.0E+06 CFU/mL	*Streptococcus equi* subsp. *equi*	1.0E+06 CFU/mL
Mycobacterium asiaticum	1.0E+06 geq/mL	*Streptococcus mitis*	1.0E+06 CFU/mL
Mycobacterium avium subsp. *avium*	1.0E+06 CFU/mL	*Streptococcus mutans*	1.0E+06 CFU/mL
Mycobacterium avium subsp. *hominissuis*	1.0E+06 CFU/mL	*Streptococcus parasanguinis*	1.0E+06 CFU/mL
Mycobacterium avium subsp. *silvaticum*	1.0E+06 CFU/mL	*Streptococcus pneumoniae*	1.0E+06 CFU/mL
Mycobacterium avium supsp. *paratuberculosis*	1.0E+06 CFU/mL	*Streptococcus pyogenes*	1.0E+06 CFU/mL
Mycobacterium bouchedurhonense	1.0E+06 CFU/mL	*Streptococcus salivarius* subsp. *salivarius*	1.0E+06 CFU/mL
Mycobacterium celatum	1.0E+06 CFU/mL	*Streptococcus sanguinis*	1.0E+06 CFU/mL
Mycobacterium chelonae	1.0E+06 CFU/mL	*Streptococcus uberis*	1.0E+06 CFU/mL
Mycobacterium chimaera	1.0E+06 CFU/mL	*Streptomyces anulatus*	1.0E+06 CFU/mL
Mycobacterium chubuense	1.0E+06 CFU/mL	*Streptomyces griseinus*	1.0E+06 CFU/mL
Mycobacterium colombiense	1.0E+06 CFU/mL	*Tsukamurella* spp.	1.0E+06 geq/mL
Mycobacterium confluentis	1.0E+06 CFU/mL	Varicella Zoster Virus	1.0E+05 cp/mL
Mycobacterium flavescens	1.0E+06 CFU/mL	*Veillonella atypica*	1.0E+06 CFU/mL
Mycobacterium fortuitum	1.0E+06 CFU/mL	*Veillonella parvula*	1.0E+06 CFU/mL
Mycobacterium fuerth	1.0E+06 CFU/mL	*Weissella paramesenteroides*	1.0E+06 CFU/mL

Interference

The effect of exogenous substances potentially secreted into respiratory specimens was evaluated (Table 21). Each potentially interfering substance was tested at or above clinically relevant levels in contrived sputum specimens in absence and presence of MTB complex target (spiked at 200 CFU/mL).

None of the substances interfered with the test performance by generating false-negative or false-positive results.

Table 21 List of exogenous substances tested for interference

Substance	Concentration	Substance	Concentration
Albuterol sulfate	0.5 µg/mL	Kanamycin monosulfate	240 µg/mL
Amikacin	80.1 µg/mL	Levofloxacin	5 mg/mL
Amoxicillin	86.4 µg/mL	Lidocaine HCl	1.2 % (w/v)
Beclomethasone	3459 pg/mL	Menthol	0.50% (w/v)
Benzocaine	1.2% (w/v)	Methyl salicylate	0.06% (v/v)
Budesonide	3 mg/mL	Mometasone	100 µg/mL
Butterbur extract	225 mg/mL	Moxifloxacin	15 µg/mL
Capreomycin	80 µg/mL	Mupirocin	5% (w/v)
Cetylpyridinium chloride	0.5% (w/v)	NaCl	5% (w/v)
Chlorhexidine gluconate	1% (v/v)	Nicotine	1 µg/mL
Cicloserin (Cycloserine)	105 µg/mL	Nystatin	1% (v/v)
Clarithromycin	20 µg/mL	Oxymetazoline	12 ng/mL
Dexamethasone	601 ng/mL	Pentamidine	1366 ng/mL
Ephedrine hydrochloride	1 mg/ml	Phenylephrine	5 mg/mL
Epinephrine	100 pg/mL	Prednisolone	3 µg/mL
Ethambutol	50 µg/mL	Pyrazinamide	240 µg/mL
Ethionamide	15 µg/mL	Rifampicin	25 µg/mL
Eucalyptol	0.002% (v/v)	Stinging Nettle Extract (500 mg)	5 mg/mL
Flunisolide	400 µg/mL	Streptomycin	240 µg/mL
Fluticasone Propionate	5 µg/mL	Sulfur	0.01% (w/v)
Formoterol Fumarate Dihydrate	66 µg/mL	Tea Tree Oil	0.50% (v/v)
Goldenseal root (capsules 570 mg)	5.7 mg/mL	Theophylline	20 µg/mL
Guaifenesin	5 mg/mL	Tobramycin	24.1 µg/mL
Isoniazid	50 µg/mL	Zanamivir	10 mg/mL

Endogenous substances that may be present in respiratory specimens were tested for interference (Table 22). Each potentially interfering substance was tested at or above clinically relevant levels in contrived sputum specimens in absence and presence of MTB complex target (spiked at 200 CFU/mL).

None of the substances interfered with the test performance by generating false-negative or false-positive results.

Table 22 List of endogenous substances tested for interference

Substance	Concentration	Substance	Concentration
Gastric juice	10% (v/v)	Mucin	5%
Hemoglobin	2 g/L	Pus	5%
Human Whole Blood	5 % (v/v)	Saliva	10% (v/v)
hDNA	4 mg/L	-	-

Whole system failure

The samples tested in the whole system failure study were contrived sputum and sputum sediment specimens spiked with MTB complex target to a concentration of approximately 3 x LoD of **cobas**® MTB in the respective matrix. The results showed that all replicates were valid and positive for MTB complex, resulting in a whole system failure rate of 0% with an upper one-sided 95% confidence interval of 3.0%.

Cross contamination

Studies were performed to evaluate potential cross contamination on the **cobas**® 6800/8800 systems using **cobas**® MTB. Cross contamination can cause false positive results. In this performance study the sample to sample cross contamination rate of **cobas**® MTB has been determined to be 0.0% (0/240) for MTB complex when alternating very high positive and negative samples were tested over multiple runs. Testing was done using contrived sputum sediment samples spiked with MTB complex target at 2 x 10^6 CFU/mL, a sample concentration generating Ct values earlier than in 95% of specimens from the infected patients in the intended use population.

Performance using clinical specimens

The performance of **cobas**® MTB using clinical samples was evaluated by testing prospective and archived specimens (raw sputum, sputum/BAL sediments) from subjects at least 18 years old with presumptive TB collected in Germany, South Africa, Switzerland, Uganda and Ukraine. Side-by-side comparison testing with the Abbott RealTi*m*e MTB assay was performed. Sensitivity and specificity were established in comparison to mycobacterial culture and AFB smear status.

Results are shown in Table 23. All positive **cobas**® MTB results for culture negative samples were confirmed to be specific amplification/detection events by post-PCR amplicon analysis.

Table 23 Sensitivity and specificity of **cobas**® MTB using clinical samples

-			Roche **cobas**® **MTB**	Abbott **RealTi*m*e MTB**
Sensitivity	**Raw Sputum**	**C+/S-**	116/134 **86.6%** [79.6 – 91.8%]	111/134 **82.8%** [75.4 – 88.8%]
		C+/S+	275/278 **98.9%** [96.9 – 99.7%]	274/278 **98.5%** [96.3 – 99.6%]
		C+/S±	391/412 **94.9%** [92.3 – 96.8%]	385/412 **93.4%** [90.6 – 95.6%]
Sensitivity	**Sediment**	**C+/S-**	116/148 **78.4%** [70.9 – 84.7%]	121/148 **81.8%** [74.6 – 87.6%]
		C+/S+	287/289 **99.3%** [97.5 – 99.9%]	284/289 **98.2%** [96.0 – 99.4%]
		C+/S±	403/437 **92.2%** [89.3 – 94.5%]	405/437 **92.6%** [89.8 – 94.9%]
Specificity	**Raw Sputum**	**C-/S-**	326/332 **98.2%** [96.1 – 99.3%]	N/A
Specificity	**Sediment**	**C-/S-**	381/393 **96.9%** [94.7 – 98.4%]	N/A
Positive Predictive Value	**Raw Sputum**	**P+**	391/397 **98.5%** [96.7 – 99.4%]	N/A

-			Roche **cobas® MTB**	Abbott **RealTi*m*e MTB**
Positive Predictive Value	**Sediment**	**P+**	403/415 **97.1%** [95.0 – 98.5%]	N/A
Negative Predictive Value	**Raw Sputum**	**P-**	326/347 **93.9%** [90.9 – 96.2%]	N/A
Negative Predictive Value	**Sediment**	**P-**	381/415 **91.8%** [88.7 – 94.3%]	N/A

C = Culture, S = AFB smear, P = PCR test

A subset of samples was tested in an external evaluation at Clinical Laboratory Services (CLS) in South Africa. For each subject, raw sputum samples were collected at two visits. One raw sputum was tested with **cobas**® MTB, Abbott RealTi*m*e MTB and GeneXpert® MTB/RIF. One raw sputum was processed to a sediment by the NALC-NaOH method and tested with **cobas**® MTB, Abbott RealTi*m*e MTB, GeneXpert® MTB/RIF and COBAS® TaqMan® MTB tests. Sensitivity and specificity were established in comparison to culture and AFB smear status.

Results are shown in Table 24.

Table 24 Sensitivity and specificity of **cobas**® MTB using clinical samples collected in South Africa

-			Roche **cobas**® **MTB**	Abbott **RealTi*m*e MTB**	Cepheid **Xpert MTB/RIF**	Roche **COBAS**® **TaqMan**® **MTB**
Sensitivity	**Raw Sputum**	**C+/S-**	18/22 **81.8%** [59.7 – 94.8%]	16/22 **72.7%** [49.8 – 89.3%]	16/22 **72.7%** [49.8 – 89.3%]	N/A
		C+/S+	72/73 **98.6%** [92.6 – 100%]	72/73 **98.6%** [92.6 – 100%]	71/73 **97.3%** [90.5 – 99.7%]	N/A
		C+/S±	90/95 **94.7%** [88.1 – 98.3%]	88/95 **92.6%** [85.4 – 97.0%]	87/95 **91.6%** [84.1 – 96.3%]	N/A
Sensitivity	**Sediment**	**C+/S-**	17/22 **77.3%** [54.6 – 92.2%]	17/22 **77.3%** [54.6 – 92.2%]	17/22 **77.3%** [54.6 – 92.2%]	13/22 **59.1%** [36.4 – 79.3%]
		C+/S+	73/73 **100%** [95.1 – 100%]	71/73 **97.3%** [90.5 – 99.7%]	73/73 **100%** [95.1 – 100%]	73/73 **100%** [95.1 – 100%]
		C+/S±	90/95 **94.7%** [88.1 – 98.3%]	88/95 **92.6%** [85.4 – 97.0%]	90/95 **94.7%** [88.1 – 98.3%]	86/95 **90.5%** [82.8 – 95.6%]
Specificity	**Raw Sputum**	**C-/S-**	193/199 **97.0%** [93.6 – 98.9%]	192/199 **96.5%** [92.9 – 98.6%]	194/199 **97.5%** [94.2 – 99.2%]	N/A
Specificity	**Sediment**	**C-/S-**	190/199 **95.5%** [91.6 – 97.9%]	189/199 **95.0%** [91.0 – 97.6%]	196/199 **98.5%** [95.7 – 99.7%]	193/196 **98.5%** [95.6 – 99.7%]
Positive Predicitive Value	**Raw Sputum**	**C+/S±**	90/96 **93.8%** [86.9-97.7%]	88/95 **92.6%** [85.4-97.0%]	87/92 **94.6%** [87.8-98.2%]	N/A
Positive Predicitive Value	**Sediment**	**C+/S±**	90/99 **90.9%** [83.4-95.8%]	88/98 **89.8%** [85.4-97.0%]	90/93 **96.8%** [90.9-99.3%]	86/89 **96.6%** [90.5-99.3%]
Negative Predicitive Value	**Raw Sputum**	**C-/S±**	193/198 **97.5%** [94.2-99.2%]	192/199 **96.5%** [92.9-98.6%]	194/202 **96.0%** [92.3-98.3%]	N/A
Negative Predicitive Value	**Sediment**	**C-/S±**	190/195 **97.4%** [94.1-99.2%]	189/196 **96.4%** [92.8-98.6%]	196/201 **97.5%** [94.3-99.2%]	193/202 **95.5%** [91.7-97.9%]

Additional information

Key assay features

Sample types	• Raw sputum • NALC-NaOH treated sputum and BAL sediments
Amount of sample processed	• ≥ 0.4 mL of patient sample treated with MIS in ratio 1:2 (total volume ≥ 1.2 mL) required in sample tube for raw sputum, instrument processes 0.85 mL • ≥ 0.2 mL of patient sample treated with MIS in ratio 1:5 (total volume ≥ 1.2 mL) required in sample tube for sputum/BAL sediment, instrument processes 0.85 mL

Symbols

The following symbols are used in labeling for Roche PCR diagnostic products.

Table 25 Symbols used in labeling for Roche PCR diagnostics products

Age/DOB Age or Date of Birth	Device not for near-patient testing	QS IU/PCR QS IU per PCR reaction, use the QS International Units (IU) per PCR reaction in calculation of the results.
SW Ancillary Software	Device not for self-testing	
Assigned Range [copies/mL] Assigned Range (copies/mL)	Distributor *(Note: The applicable country/region may be designated beneath the symbol)*	SN Serial number
Assigned Range [IU/mL] Assigned Range (IU/mL)	Do not re-use	Site Site
EC REP Authorized representative in the European Community	Female	Procedure Standard Standard Procedure
BARCODE Barcode Data Sheet	For IVD performance evaluation only	STERILE EO Sterilized using ethylene oxide
LOT Batch code	GTIN Global Trade Item Number	Store in dark
Biological risks	Importer	Temperature limit
REF Catalogue number	IVD In vitro diagnostic medical device	TDF Test Definition File
CE CE marking of conformity; this device is in conformity with the applicable requirements for CE marking of an in vitro diagnostic medical device	LLR Lower Limit of Assigned Range	This way up
	Male	Procedure UltraSensitive Ultrasensitive Procedure
Collect Date Collect date	Manufacturer	UDI Unique Device Identifier
Consult instructions for use	CONTROL − Negative control	ULR Upper Limit of Assigned Range
Σ Contains sufficient for <*n*> tests	NON STERILE Non-sterile	Urine Fill Line Urine Fill Line
CONTENT Content of kit	Patient Name	Rx only For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.
CONTROL Control	Patient number	Use-by date
Date of manufacture	Peel here	
Device for near-patient testing	CONTROL + Positive control	
Device for self-testing	QS copies / PCR QS copies per PCR reaction, use the QS copies per PCR reaction in calculation of the results.	

Technical support

For technical support (assistance) please reach out to your local affiliate:
https://www.roche.com/about/business/roche_worldwide.htm

Manufacturer

Table 26 Manufacturer

Manufactured in the United States

Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim, Germany
www.roche.com

Made in USA

Trademarks and patents

See https://diagnostics.roche.com/us/en/about-us/patents

Copyright

CE 0123

IVD

References

1. Global tuberculosis report 2023. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.
2. Sitthidet Tharinjaroen C, Intorasoot S, Anukool U, et al. Novel targeting of the lepB gene using PCR with confronting two-pair primers for simultaneous detection of *Mycobacterium tuberculosis* complex and *Mycobacterium bovis*. *J Med Microbiol.* 2016;65:36-43.
3. Rajbhandari, R.M., de la Fuente, J., Karmacharya, D. et al. Understanding Mycobacterium tuberculosis complex in elephants through a One Health approach: a systematic review. BMC Vet Res 18, 262 (2022). https://doi.org/10.1186/s12917-022-03356-8.
4. Alexander KA, Laver PN, Michel AL, et al. Novel *Mycobacterium tuberculosis* complex pathogen*, M. mungi*. *Emerg Infect Dis*. 2010;16:1296-9.
5. Novosad SA, Winthrop KL. Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae. *Clin Infect Dis.* 2014;58:1587-98.
6. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. *MMWR Recomm Rep*. 2000;49:1-51.
7. Centers for Disease Control Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. *MMWR Morb Mortal Wkly Rep*. 2011;60:1650-3.
8. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. *Lancet Infect Dis*. 2009;9:153-61.
9. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. *Gene*. 1990;93:125-8.
10. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. *Biotechnology (N Y)*. 1992;10:413-7.
11. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. *Genome Res*. 1996;6:986-94.
12. Chosewood LC, Wilson DE, eds. *Biosafety in Microbiological and Biomedical Laboratories.* 5th ed. HHS Publication No. (CDC) 21-1112. US Department of Health and Human Services; 2009.
13. Clinical and Laboratory Standards Institute. *Protection of Laboratory Workers from Occupationally Acquired Infections*. 4th ed. M29-A4. Clinical and Laboratory Standards Institute: Wayne, PA; 2014.
14. World Health Organization. *Tuberculosis Laboratory Biosafety Manual*. WHO: Geneva, Switzerland; 2012.
15. Kent PT, Kubica GP. *Public Health Mycobacteriology: A Guide for the Level III Laboratory*. Centers for Disease Control: Atlanta, GA; 1985.

Document revision

Document Revision Information	
Doc Rev. 2.0 05/2024	Update biosafety guidance for adaptation to local regulations, grammar corrections, and WHO data/reference. Moved "at least 18 years old" from **Procedural limitations** to **Performance using clinical specimens**. Updated **cobas**® branding. Updated competent authority statement. Removed Rx Only from the front page. Updated the harmonized symbol page. Please contact your local Roche Representative if you have any questions.
Doc Rev. 3.0 12/2024	Added system software version 2.0 information for **cobas**® 6800/8800 systems. Updated display of example results on **cobas**® 6800/8800 systems with software version 1.4. P/Ns of consumables removed, detailed information on consumables are referenced in the **cobas**® 5800 and **cobas**® 6800/8800 systems User Assistance. Please contact your local Roche Representative if you have any questions

The summary of safety and performance report can be found using the following link: https://ec.europa.eu/tools/eudamed